Astrazeneca (AZN) news
Recent news
Insitro: To receive single-digit royalties on potential global commercial sales from AstraZeneca collaboration
AInvest Wire · 7h agoImportantAstraZeneca and Insitro ink $1.86B AI drug discovery deal
AInvest Wire · 7h agoKyntra Bio, Inc.: Maxim Group initiates coverage with buy rating; target price $35
Maxim Group, a well-established investment bank, has initiated coverage of Kyntra Bio, Inc. (NASDAQ: KYNB) with a "Buy" rating and a target price of $35 per share. This move comes amid a period of strategic repositioning for the biopharmaceutical company, which rebranded from FibroGen in early 2026…
AInvest Wire · 2d agoAstraZeneca - EFZimfotase alpha shows improvement in primary and key secondary endpoints at week 25 and week 49
AstraZeneca’s investigational enzyme replacement therapy, efzimfotase alfa (ALXN1850), has demonstrated improvements in both primary and key secondary endpoints in its Phase III clinical trials for the treatment of hypophosphatasia (HPP), a rare inherited metabolic disorder. The results, reported…
AInvest Wire · 3d agoAstraZenca's Breztri Aerosphere inhaler NDA gets FDA approval
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) as maintenance treatment for COPD . This approval follows the successful completion of two clinical trials, including the phase 3 ETHOS trial, which evaluated…
AInvest Wire · 6d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.